-- China's drug regulator approved Haisco Pharmaceutical's (SHE:002653) clinical trial for its HSK47388 tablets, according to a Thursday disclosure to the Shanghai bourse.
The tablets are indicated for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.